daunorubicin has been researched along with pk 11195 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appelbaum, FR; Banker, DE; Cooper, JJ; Cotter, FE; Fennell, DA; Willman, CL | 1 |
| Chorvath, B; Duraj, J; Hunakova, L; Jakubikova, J; Sedlak, J | 1 |
2 other study(ies) available for daunorubicin and pk 11195
| Article | Year |
|---|---|
PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Resistance, Multiple; Flow Cytometry; Humans; Isoquinolines; Leukemia, Myeloid; Ligands; Receptors, GABA-A; Tumor Cells, Cultured | 2002 |
PK11195, an isoquinoline carboxamide ligand of the mitochondrial benzodiazepine receptor, increased drug uptake and facilitated drug-induced apoptosis in human multidrug-resistant leukemia cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carcinoma; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluoresceins; Fluorescent Dyes; HL-60 Cells; Humans; Isoquinolines; Leukemia, Myeloid; Ligands; Mitochondrial Proteins; Ovarian Neoplasms; Receptors, GABA-A; Tumor Cells, Cultured | 2002 |